Currently, several clinical trials are ongoing for novel treatment strategies for moderate-to-severe stages of CD, including trials for different monoclonal antibodies [74–76], JAK1 inhibitors, the potential use of fecal transplantation [77, 78], and mesenchymal adult stem cells strategies [79, 80]. Here, JAK1 is linked to Cowden disease.